Dr. Natalie Klar, MD, a breast oncologist at NYU Langone’s Perlmutter Cancer Center, says that every woman is at risk for ...
Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, ...
GU ASCO annual meeting featured a urothelial carcinoma session and a presentation by Dr. Nataliya Mar discussing real world toxicity profile of enfortumab vedotin with or without pembrolizumab in ...
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Hosted on MSN2h
Nine lesser-known symptoms of most common childhood cancerA cancer awareness advocate has highlighted nine lesser-known signs of the most prevalent form of the disease in children, ...
Excess body weight—including overweight and obesity—is a significant risk factor for cancer. Research from the American Cancer Society estimates that it contributes to approximately 5 percent of ...
Findings also suggested that an up-front dose reduction of enfortumab vedotin may benefit older patients with urothelial carcinoma.
More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback